Literature DB >> 3921672

No difference in sensitivity for occult infection between tropolone- and oxine-labeled indium-111 leukocytes.

F L Datz, R A Bedont, W J Baker, N P Alazraki, A Taylor.   

Abstract

There is considerable disagreement as to whether oxine or tropolone is the best labeling agent for indium leukocytes. We have previously looked at the sensitivity of oxine-labeled 111In leukocyte scans for occult infections and now present a similar group of patients imaged with tropolone-labeled 111In leukocytes. Thirty-four patients (38 studies) with possible occult infection were prospectively studied. Patients were imaged 1-4 hr after injection and again at 24 hr postinjection. The early tropolone images had a sensitivity of 53% while the delayed images at 24 hr had a sensitivity of 93%. Based on a previous study, oxine-labeled leukocyte scans have an early sensitivity of 33% and a delayed sensitivity (at 24 hr) of 95%. The differences in sensitivity between oxine and tropolone when imaged early and at 24 hr were not statistically significant. We conclude that there is no significant difference in the ability to detect infection between oxine- and tropolone-labeled leukocytes, both early at 1-4 hr, and on delayed imaging 24 hr after injection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921672

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  Should platelets be labelled in plasma or saline? Consider the clinical indication.

Authors:  A M Peters
Journal:  Eur J Nucl Med       Date:  1991

2.  Can 111indium autologous mixed leucocyte scanning accurately assess disease extent and activity in Crohn's disease?

Authors:  R H Park; J H McKillop; A Duncan; J F MacKenzie; R I Russell
Journal:  Gut       Date:  1988-06       Impact factor: 23.059

3.  In vitro human leukocyte labeling with (64)Cu: an intraindividual comparison with (111)In-oxine and (18)F-FDG.

Authors:  Kuldeep K Bhargava; Raj K Gupta; Kenneth J Nichols; Christopher J Palestro
Journal:  Nucl Med Biol       Date:  2009-05-07       Impact factor: 2.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.